Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pharmacokinetic study of ceftriaxone regimens for outpatient use in Enterococcus faecalis infective endocarditis
2017-003127-29Phase 2Active
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ceftriaxone in endocarditis (IE) and Enterococcal endocarditis (EE) (2 arms), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoints: Ceftriaxone serum concentration at 24 hours after a single 4 g short infusion and Proportion or determination of subjects with ceftriaxone serum concentration above 5 micrograms/mL at 24 hours. Started Dec 2017; status: active.
02
Drugs
ceftriaxone
03
Conditions
endocarditis (IE)Enterococcal endocarditis (EE)
Beyond the preview
Go deeper on 2017-003127-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003127-29.